Evidence map›Paper›PMID 39696918›Full record

ArticleJournal of cellular physiology2025

CBFβ Regulates RUNX3 ADP-Ribosylation to Mediate Homologous Recombination Repair.

William E Samsa, Zhen Zhang, Zihua Gong

Abstract read
In one paragraph

Article in Journal of cellular physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

William E SamsaDepartment of Cancer Biology, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA.
Zhen ZhangDepartment of Cancer Biology, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA.
Zihua GongDepartment of Cancer Biology, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA.ORCID 0000-0002-8008-0615

Funding

The role of NUDT16 in DNA damage response and tumorigenesisR01CA222195 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI Zihua Gong · 2019 to 2026
$3.8M
NCI NIH HHS R01 CA222195
6 · The paper itself

Abstract

RUNX3 is a master developmental transcriptional factor that has been implicated as a tumor suppressor in many cancers. However, the exact role of RUNX3 in cancer pathogenesis remains to be completely elucidated. Recently, it has emerged that RUNX3 is involved in the DNA damage response. Here, we demonstrate that heterodimerization of RUNX3 with CBFβ is necessary for its stability by protecting RUNX3 from RUNX3 ADP-ribosylation-dependent ubiquitination and degradation. We further identify new amino acid residues that are targets for PARylation and demonstrate that RUNX3 PARylation at these residues is necessary for localization of RUNX3 to DNA double strand break sites (DBSs). We also demonstrate that both RUNX3 PARylation and CBFβ heterodimerization with RUNX3 positively regulates homologous recombination (HR) repair, in part by promoting the recruitment of CtIP and phospho-RPA2 to the DBSs to mediate HR repair. In summary, we provide evidence that RUNX3 regulates HR repair activity in a PARylation-dependent manner.

Indexed as

ADP-RibosylationCore Binding Factor Alpha 3 SubunitCore Binding Factor beta SubunitRecombinational DNA RepairDNA Breaks, Double-StrandedEndodeoxyribonucleasesHEK293 CellsHumansNuclear ProteinsProtein MultimerizationUbiquitinationCBFB protein, humanCore Binding Factor Alpha 3 SubunitCore Binding Factor beta SubunitEndodeoxyribonucleasesNuclear ProteinsRBBP8 protein, humanRunx3 protein, humanADP‐ribosylationCBFβhomologous recombination repairRUNX3

Identifiers

PMID39696918
PMCPMC12131651

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.